How to Get Belsomra (Suvorexant) in Tennessee

What Is Suvorexant and Why Does It Matter for Insomnia?

Suvorexant is a dual orexin receptor antagonist (DORA) that blocks wake-promoting orexin-A and orexin-B neuropeptides in the lateral hypothalamus, reducing the neurological drive to stay awake rather than sedating the brain globally. The FDA approved Belsomra in August 2014 for the treatment of insomnia characterized by difficulty with sleep onset and sleep maintenance in adults (FDA approval label).

The registration trial by Herring et al. (Lancet Neurology, 2014) enrolled 3,291 patients across two phase 3 studies. Patients taking suvorexant 20 mg fell asleep approximately 8 minutes faster than placebo at month 1 (subjective sleep onset latency) and gained roughly 16 minutes of total sleep time per night over 3 months. The drug also improved sleep maintenance, with wake-after-sleep-onset reductions that persisted through the study period.

This mechanism matters. Unlike benzodiazepine receptor agonists (e.g., zolpidem), which enhance GABAergic inhibition, suvorexant does not carry the same risk of respiratory depression, making it a reasonable option for patients with mild-to-moderate obstructive sleep apnea (Ueno et al., J Clin Sleep Med, 2020). The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline conditionally recommends suvorexant for sleep maintenance insomnia (Sateia et al., J Clin Sleep Med, 2017).

Tennessee Telehealth Prescribing Rules for Belsomra

Tennessee law allows prescribers to write prescriptions for Schedule IV controlled substances like suvorexant via telehealth. This is legal. The Tennessee Board of Medical Examiners requires that the telehealth visit establish a legitimate provider-patient relationship, which can occur through a live, synchronous audio-video encounter.

A prescriber in Tennessee (or a prescriber licensed in Tennessee through an interstate compact) may evaluate the patient, document a clinical assessment, and transmit an electronic prescription to the patient's pharmacy of choice. Tennessee adopted permanent telehealth prescribing rules following the post-pandemic regulatory update in 2023, which expanded access to controlled substance prescribing via telehealth beyond the initial emergency flexibilities (Tennessee Board of Medical Examiners).

For patients in rural counties (and Tennessee has 70 counties classified as rural by the Health Resources and Services Administration), telehealth removes a significant geographic barrier. A patient in Hardin County, for example, does not need to drive 90 minutes to Memphis for a sleep specialist visit. The telehealth visit itself typically lasts 15 to 25 minutes.

One practical note: some telehealth platforms will not prescribe Schedule IV medications on the first visit and instead require a follow-up appointment before writing the prescription. Ask about this before booking.

Who Can Prescribe Belsomra in Tennessee?

Three categories of clinicians hold prescriptive authority for suvorexant in Tennessee.

Physicians (MD/DO): Any licensed physician can prescribe Belsomra. No additional certification is required beyond a valid DEA registration and Tennessee medical license. Sleep medicine board certification is helpful but not mandatory for prescribing a Schedule IV hypnotic.

Nurse Practitioners (NPs): Tennessee NPs with a certificate of fitness may prescribe Schedule II through V controlled substances under a collaborative agreement with a physician. The supervising physician does not need to be physically present, but the written agreement must be on file with the Tennessee Board of Nursing (Tennessee Code 63-7-123). NPs with more than 24 months of clinical experience and at least 4,000 practice hours may prescribe independently under the 2020 APRN modernization act.

Physician Assistants (PAs): Tennessee PAs can prescribe Schedule III through V controlled substances. Because suvorexant is Schedule IV, PAs may prescribe it under their supervising physician relationship. The supervising physician must have approved the PA's prescriptive authority in their practice agreement.

All three provider types can conduct the prescribing visit via telehealth.

Pharmacy Access and 503A Compounding in Tennessee

Belsomra is available at retail chain pharmacies (CVS, Walgreens, Walmart) and independent pharmacies across Tennessee. Because it is a Schedule IV substance, the prescription must be transmitted electronically or by a signed hard-copy prescription (verbal/phone-in orders for Schedule IV are permitted under DEA regulations, though many pharmacies prefer e-prescribing).

Tennessee also licenses 503A compounding pharmacies that may prepare suvorexant formulations under a patient-specific prescription. A 503A pharmacy may compound suvorexant into alternative dosage forms (such as a suspension for patients who have difficulty swallowing tablets) provided the prescription is for an identified individual patient and the pharmacy complies with USP <795> standards.

The Tennessee Board of Pharmacy maintains a searchable registry of licensed compounding pharmacies. As of 2026, there are approximately 45 pharmacies in Tennessee holding active 503A compounding licenses. These pharmacies can ship within the state.

Patients should confirm with their pharmacy that suvorexant is in stock before the prescriber transmits the prescription. Brand-name Belsomra tablets (5 mg, 10 mg, 15 mg, 20 mg) are the only commercially available form, as no FDA-approved generic suvorexant exists yet. Out-of-stock situations can delay fills by 1 to 3 business days.

Insurance Coverage and TennCare Limitations

This is the most common barrier Tennessee patients face. TennCare (Tennessee's Medicaid program) does not cover Belsomra for insomnia. The TennCare formulary restricts orexin receptor antagonists to patients with a type 2 diabetes indication only, which does not apply to most insomnia patients.

Commercial insurance: Most major commercial plans (BlueCross BlueShield of Tennessee, Cigna, UnitedHealthcare, Aetna) include Belsomra on their formularies but place it on a non-preferred brand tier (typically Tier 3 or Tier 4). This means the copay can range from $40 to $75 per month, and prior authorization is almost always required.

Medicare Part D: Belsomra is listed on most Medicare Part D formularies but again on higher tiers. Patients in the coverage gap (the "donut hole") may pay significantly more. The 2025 Inflation Reduction Act $2,000 annual out-of-pocket cap helps offset costs for Medicare beneficiaries taking high-tier brand medications.

Cash price: Without insurance, Belsomra costs approximately $400 to $450 for 30 tablets. Merck offers a savings card that can reduce the copay to as low as $15 per month for commercially insured patients (Merck patient assistance programs). GoodRx and similar discount platforms may reduce cash prices to the $340 to $380 range.

The gap between commercial coverage and TennCare non-coverage creates a two-tier system. Roughly 1.7 million Tennesseans are enrolled in TennCare (Kaiser Family Foundation, 2024), and those patients are effectively locked out of DORA-class medications for insomnia unless they can pay cash or find alternative funding.

Prior Authorization: What Documentation Tennessee Insurers Require

Nearly every commercial plan in Tennessee requires prior authorization (PA) before covering Belsomra. The PA process typically takes 3 to 7 business days for initial review. Here is what the insurer will request.

Clinical documentation needed for PA:

1. A confirmed diagnosis of insomnia disorder (ICD-10 code G47.00 or G47.01)
2. Documentation that the patient has tried and failed at least one first-line therapy, usually cognitive behavioral therapy for insomnia (CBT-I) or a generic hypnotic (zolpidem, eszopiclone, or trazodone)
3. Duration of insomnia symptoms (most plans require at least 3 months of documented symptoms)
4. Sleep diary or validated questionnaire score (Insomnia Severity Index, Pittsburgh Sleep Quality Index)
5. Prescriber notes explaining why the DORA mechanism is preferred over alternatives

Some plans specifically require a trial-and-failure of two generic medications before approving Belsomra. BlueCross BlueShield of Tennessee, the largest commercial insurer in the state, requires documentation of inadequate response to at least one generic sleep medication according to its 2025 formulary criteria.

If the PA is denied, patients have the right to a formal appeal. The first-level appeal typically requires a peer-to-peer review between the prescriber and the plan's medical director. Tennessee's Department of Commerce and Insurance oversees external review processes for patients who exhaust internal appeals.

What Labs and Evaluations Are Needed Before Starting Belsomra?

Suvorexant does not require routine blood work or organ-function monitoring before or during treatment. This is a meaningful advantage over some older hypnotics.

The clinical evaluation focuses on ruling out conditions that mimic or complicate insomnia. Before prescribing, most providers in Tennessee will assess the following:

Sleep history and screening: A structured clinical interview or validated screening questionnaire (e.g., STOP-BANG for obstructive sleep apnea, Epworth Sleepiness Scale for excessive daytime somnolence). If obstructive sleep apnea is suspected, a home sleep test or in-lab polysomnography should be completed before initiating Belsomra. Suvorexant is not contraindicated in mild-to-moderate OSA, but untreated severe OSA requires separate management.

Medication reconciliation: Suvorexant is metabolized by CYP3A4. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir) are contraindicated with suvorexant because they increase plasma concentrations substantially. Moderate CYP3A4 inhibitors (diltiazem, erythromycin, fluconazole, verapamil) require a dose reduction to no more than 5 mg nightly (FDA prescribing information).

Mental health assessment: The FDA label carries a warning about suicidal ideation, particularly in patients with pre-existing depression. Screening with the PHQ-9 or a brief clinical interview before prescribing is standard practice.

Substance use history: As a Schedule IV substance, prescribers must verify there is no active substance use disorder that would make a controlled hypnotic inappropriate. Tennessee's Controlled Substance Monitoring Database (CSMD) must be checked before prescribing (Tennessee CSMD).

No hepatic function panels, renal function tests, or metabolic panels are required, though clinicians may order them as part of a general intake evaluation.

How Long Until You Receive Belsomra After a Tennessee Visit?

The timeline depends on the insurance pathway.

No prior authorization needed (cash pay or pre-approved plan): The prescriber can e-prescribe during or immediately after the telehealth visit. If the pharmacy has Belsomra in stock, the patient can pick it up same-day. For mail-order pharmacies, expect 2 to 5 business days.

Prior authorization required: Add 3 to 7 business days for the PA review. If approved on first submission, the total time from visit to medication in hand is typically 5 to 10 business days. If the PA is denied and requires appeal, add another 10 to 30 days.

503A compounding pharmacy: Compounded preparations typically require 3 to 7 business days for preparation after the prescription is received. Shipping within Tennessee adds 1 to 3 days.

The fastest path for a Tennessee patient is a telehealth visit followed by a cash-pay e-prescription to a local retail pharmacy. From booking the appointment to picking up the medication, this can happen within 24 to 48 hours.

Transferring a Belsomra Prescription to Tennessee

Patients relocating to Tennessee from another state can transfer an existing Belsomra prescription under specific conditions. DEA regulations permit one transfer of a Schedule III through V prescription between pharmacies. The receiving Tennessee pharmacy contacts the originating out-of-state pharmacy to verify the prescription and transfer the remaining refills.

Tennessee Board of Pharmacy rules require the receiving pharmacist to verify:

1. The prescription has remaining refills (Schedule IV prescriptions expire 6 months from the date written)
2. The prescriber is licensed and DEA-registered
3. The originating pharmacy is licensed in its state

If the prescription has no remaining refills, the patient needs a new evaluation from a Tennessee-licensed prescriber. A telehealth visit can satisfy this requirement. Patients should bring their medication bottle and prior pharmacy records to the new appointment.

Clinical Considerations Specific to Tennessee's Patient Population

Tennessee ranks 7th nationally in obesity prevalence, with 39.5% of adults classified as obese (BMI 30 or greater) according to CDC BRFSS 2023 data. Obesity is a major risk factor for obstructive sleep apnea, which frequently co-occurs with insomnia (a condition termed COMISA, or co-morbid insomnia and sleep apnea). Suvorexant's favorable respiratory profile compared to benzodiazepine receptor agonists makes it a particularly relevant option for this population. The Ueno et al. 2020 study found that suvorexant did not worsen the apnea-hypopnea index in patients with mild-to-moderate OSA, while zolpidem use has been associated with worsened respiratory events during sleep.

Tennessee also has one of the highest per-capita opioid prescribing rates in the United States. Opioid-induced sleep disruption is common, and choosing a non-GABAergic hypnotic like suvorexant over a benzodiazepine or Z-drug reduces the additive risk of respiratory depression in patients on concurrent opioid therapy.

The state's CSMD check requirement provides an additional safety layer. Tennessee law mandates that prescribers query the CSMD before writing any Schedule II through IV prescription, allowing the clinician to identify concurrent controlled substance use before adding a hypnotic.

Cost Comparison: Belsomra vs. Generic Alternatives in Tennessee

For patients weighing cost, the price differential between Belsomra and generic alternatives is substantial.

| Medication | Schedule | 30-Day Cash Price (approx.) | Generic Available | |---|---|---|---| | Suvorexant (Belsomra) 10 mg | IV | $400-$450 | No | | Zolpidem (Ambien) 10 mg | IV | $8-$15 | Yes | | Eszopiclone (Lunesta) 3 mg | IV | $10-$20 | Yes | | Trazodone 50 mg (off-label) | Not scheduled | $4-$8 | Yes | | Lemborexant (Dayvigo) 5 mg | IV | $350-$400 | No |

The AASM 2017 guideline does not rank DORAs above Z-drugs in efficacy for all patients (Sateia et al., J Clin Sleep Med, 2017). The choice often comes down to comorbidity profile, prior treatment failures, and side-effect tolerance. Patients who have failed or cannot tolerate generic options have the strongest clinical and insurance-approval case for suvorexant.

Merck's patient assistance program accepts applications from uninsured or underinsured Tennessee residents with household income at or below 400% of the federal poverty level. Approved patients may receive Belsomra at no cost for up to 12 months, renewable annually.